Form 4: Allogene CEO Sells Shares for Tax, Gains Options & RSUs

Allogene Therapeutics' President and CEO, David D. Chang, reported a non-discretionary sale of shares to cover tax obligations, alongside new grants of stock options and restricted stock units.

Summary

• David D. Chang, President and CEO, and Director of Allogene Therapeutics, Inc. (ALLO), filed a Form 4 detailing recent equity transactions.
• On February 2, 2026, Chang sold 95,269 shares of Common Stock at a weighted average price of $1.80 per share, with individual sales ranging from $1.71 to $1.87.
• This sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plan to satisfy tax withholding obligations related to the vesting of restricted stock units, and was not a discretionary trade.
• Chang acquired 1,387,931 stock options with an exercise price of $1.87, which will vest 25% on February 2, 2027, and the remaining shares in 36 equal monthly installments thereafter, expiring on February 2, 2036.
• Chang also acquired 392,586 Restricted Stock Units (RSUs), which will vest in four successive equal annual installments over a four-year period measured from February 2, 2026, subject to continued service.
• Following these transactions, Chang directly owns 5,185,862 shares of Common Stock and indirectly owns 2,913,196 shares through various trusts (RTC 2019 Trust, JEC 2019 Trust, and Chang 2006 Family Trust).
• He also directly owns 1,387,931 stock options and 392,586 RSUs.
• The filing also notes the acquisition of 4,562 shares of the Issuer's common stock by the reporting person on September 15, 2025, pursuant to an employee stock purchase program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The non-discretionary 'sell to cover' transaction is a routine event, while the significant grants of stock options and RSUs demonstrate continued long-term incentive alignment for the CEO.

Positives

• The grant of 1,387,931 stock options and 392,586 Restricted Stock Units (RSUs) indicates continued long-term incentive and alignment of the CEO's interests with shareholder value.
• The sale of 95,269 shares was explicitly a non-discretionary 'sell to cover' transaction for tax withholding, rather than a discretionary sale, which mitigates concerns about management's confidence in the company.

Negatives

• The sale of 95,269 shares, even for tax purposes, reduces the CEO's direct beneficial ownership of common stock.
• The weighted average sale price of $1.80 per share for the 'sell to cover' transaction is relatively low, potentially reflecting current market valuation.

Future Outlook

The filing details future vesting schedules for stock options and restricted stock units, indicating a long-term incentive structure for the CEO. Stock options will vest 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, expiring on February 2, 2036. Restricted Stock Units will vest in four successive equal annual installments over a four-year period measured from February 2, 2026.

Management Comments

• "The sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person."
• "The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."

Industry Context

StockSavvy.ai notes that equity compensation, including stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries to align executive incentives with long-term shareholder value. 'Sell to cover' transactions for tax purposes are also common and generally not viewed as a negative signal of management's confidence, unlike discretionary sales.

Comparison to Industry Standards

• The grant of stock options and RSUs to a President and CEO is a standard compensation practice in the biotech sector, comparable to incentive structures seen at companies like Gilead Sciences or Amgen, which use similar long-term equity awards to retain and motivate key executives.
• The 'sell to cover' mechanism for tax withholding is a widely adopted method across U.S. public companies, including peers in the biotech industry, to manage tax liabilities arising from equity vesting, rather than requiring executives to fund these obligations out of pocket.

Related Party Transactions

• Securities held indirectly in the name of the RTC 2019 Trust dated October 1, 2019.
• Securities held indirectly in the name of the JEC 2019 Trust dated October 1, 2019.
• Securities held indirectly in the name of the Chang 2006 Family Trust.

Stakeholder Impact

• Shareholders: The 'sell to cover' transaction has a minimal dilutive effect, but the new equity grants align the CEO's long-term interests with shareholder value.
• Employees: The mention of an employee stock purchase program (ESPP) indicates broader employee equity participation opportunities.

Next Steps

• Vesting of 25% of stock options on February 2, 2027, with subsequent monthly vesting over 36 months.
• Annual vesting of Restricted Stock Units over four years from February 2, 2026.

Key Dates

Recommendation

This Form 4 primarily details routine executive compensation and a non-discretionary tax-related stock sale. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The new equity grants are a standard incentive mechanism, and the 'sell to cover' is a common, non-discretionary event.

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Transaction, David D. Chang, CEO, Stock Options, Restricted Stock Units, Equity Compensation, Sell to Cover